Doliver Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.12M | Sell |
16,522
-689
| -4% | -$80.6K | 0.48% | 30 |
|
|
2026
Q1 | $2.07M | Sell |
17,211
-380
| -2% | -$43.9K | 0.47% | 27 |
|
|
2025
Q4 | $1.85M | Sell |
17,591
-187
| -1% | -$17.6K | 0.46% | 37 |
|
|
2025
Q3 | $1.49M | Sell |
17,778
-265
| -1% | -$21.8K | 0.39% | 45 |
|
|
2025
Q2 | $1.43M | Buy |
18,043
+1,380
| +8% | +$110K | 0.39% | 44 |
|
|
2025
Q1 | $1.5M | Buy |
16,663
+316
| +2% | +$29.5K | 0.42% | 37 |
|
|
2024
Q4 | $1.63M | Buy |
16,347
+3,260
| +25% | +$336K | 0.45% | 35 |
|
|
2024
Q3 | $1.49M | Sell |
13,087
-246
| -2% | -$29.2K | 0.41% | 43 |
|
|
2024
Q2 | $1.65M | Sell |
13,333
-99
| -0.7% | -$12.8K | 0.46% | 33 |
|
|
2024
Q1 | $1.77M | Sell |
13,432
-433
| -3% | -$53.4K | 0.5% | 31 |
|
|
2023
Q4 | $1.51M | Sell |
13,865
-20
| -0.1% | -$2.08K | 0.46% | 38 |
|
|
2023
Q3 | $1.43M | Buy |
13,885
+144
| +1% | +$15.5K | 0.43% | 34 |
|
|
2023
Q2 | $1.59M | Sell |
13,741
-85
| -0.6% | -$9.65K | 0.48% | 30 |
|
|
2023
Q1 | $1.47M | Buy |
13,826
+326
| +2% | +$35.2K | 0.46% | 32 |
|
|
2022
Q4 | $1.5M | Sell |
13,500
-736
| -5% | -$75.2K | 0.49% | 29 |
|
|
2022
Q3 | $1.23M | Sell |
14,236
-543
| -4% | -$48.5K | 0.45% | 33 |
|
|
2022
Q2 | $1.35M | Buy |
14,779
+3,410
| +30% | +$302K | 0.48% | 34 |
|
|
2022
Q1 | $933K | Buy |
11,369
+1,055
| +10% | +$83.2K | 0.3% | 63 |
|
|
2021
Q4 | $810K | Sell |
10,314
-2,838
| -22% | -$226K | 0.25% | 66 |
|
|
2021
Q3 | $988K | Buy |
13,152
+965
| +8% | +$73.4K | 0.33% | 62 |
|
|
2021
Q2 | $948K | Buy |
12,187
+323
| +3% | +$24K | 0.31% | 53 |
|
|
2021
Q1 | $873K | Buy |
11,864
+1,965
| +20% | +$145K | 0.32% | 49 |
|
|
2020
Q4 | $773K | Buy |
9,899
+1,036
| +12% | +$79.2K | 0.34% | 51 |
|
|
2020
Q3 | $702K | Buy |
8,863
+246
| +3% | +$19.3K | 0.36% | 55 |
|
|
2020
Q2 | $636K | Buy |
8,617
+856
| +11% | +$64.4K | 0.28% | 56 |
|
|
2020
Q1 | $622K | Buy |
7,761
+1,737
| +29% | +$137K | 0.31% | 48 |
|
|
2019
Q4 | $523K | Sell |
6,024
-375
| -6% | -$30.8K | 0.21% | 50 |
|
|
2019
Q3 | $519K | Buy |
6,399
+1,378
| +27% | +$110K | 0.21% | 52 |
|
|
2019
Q2 | $402K | Hold |
5,021
| – | – | 0.16% | 51 |
|
|
2019
Q1 | $398K | Sell |
5,021
-147
| -3% | -$11K | 0.16% | 50 |
|
|
2018
Q4 | $377K | Sell |
5,168
-862
| -14% | -$60.9K | 0.19% | 70 |
|
|
2018
Q3 | $408K | Sell |
6,030
-210
| -3% | -$13.4K | 0.17% | 73 |
|
|
2018
Q2 | $361K | Sell |
6,240
-781
| -11% | -$44.1K | 0.15% | 97 |
|
|
2018
Q1 | $365K | Buy |
7,021
+1,129
| +19% | +$61K | 0.16% | 112 |
|
|
2017
Q4 | $316K | Buy |
5,892
+2,215
| +60% | +$123K | 0.13% | 145 |
|
|
2017
Q3 | $225K | Buy |
+3,677
| New | +$223K | 0.1% | 195 |
|
Other funds holding MRK
ECSS
Doliver Advisors's MRK Position: Q2 2026 in Review
Doliver Advisors reduced its Merck (MRK) stake by 4% in Q2 2026, selling an estimated $80.6K and leaving 16,522 shares worth $2.12M. The position accounts for 0.48% of the portfolio, ranked #30.
Doliver Advisors first reported a position in MRK in Q3 2017 and has held it in 36 quarters since. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Doliver Advisors held 16,522 shares of Merck worth $2.12M as of Q2 2026.
- Doliver Advisors sold 689 Merck shares in Q2 2026, an estimated $80.6K.
- Merck made up 0.48% of Doliver Advisors's portfolio in Q2 2026, its #30 holding.
- Doliver Advisors first reported a position in Merck in Q3 2017 and has held it in 36 quarters since.
- 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.